<DOC>
	<DOCNO>NCT02287129</DOCNO>
	<brief_summary>Metabolic Molecular Response evaluation individualization therapy adenocarcinoma gastroesophageal junction evaluation R0 resection rate patient metabolically ( ie , accord PET criterion ) chemotherapy-resistant locally advanced AEG , receive intensify neoadjuvant chemoradiotherapy ( INRCT ) . Additonal effort do investigation molecular metabolic biomarkers relation predictive prognostic value correlate histopathologic response clinical outcome exploratory approach .</brief_summary>
	<brief_title>Evaluation Individualization Therapy Adenocarcinomas Gastroesophageal Junction</brief_title>
	<detailed_description>Adenocarcinomas esophagus esophagogastric junction ( AEG ) clinically-topographically divided subtypes I-III accord Siewert classification show increase incidence . Neoadjuvant and/or perioperative chemotherapy preoperative radiochemotherapy well establish management AEG . However , significant number patient respond preoperative chemotherapy , suffer toxicity face bad outcome due low R0 resection rate . Previous result MUNICON-1 MUNICON-2 trial show PET-based therapy individualization successfully integrated neoadjuvant treatment algorithm . Tumor-free resection edge ( R0 ) constitute great prognostic advantage term overall survival . However , R0 resection rate patient , accord early metabolic response evaluation , respond chemotherapy , satisfactory , even conversion - albeit moderate - radiochemotherapy MUNICON-2 trial . Thus , patient population ( so-called non responder ) far lack beneficial neoadjuvant therapy modality . Based result , primary goal MEMORI study evaluate R0 resection rate patient metabolically ( ie , accord PET criterion ) chemotherapy-resistant locally advanced AEG , receive intensify neoadjuvant chemoradiotherapy ( INRCT ) . Secondary plan investigate molecular metabolic biomarkers relation predictive prognostic value correlate histopathologic response clinical outcome exploratory approach .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Histologically confirm AEG IIII Potentially R0 resectable AEG primary tumor category UT2 4 Functional operability : Exclusion OP limit comorbidities Intense FDG tracer uptake tumor Baseline PET/CT examination thus suitability monitor early response prediction FDG PET ( [ 18F ] FDG uptake tumor baseline &gt; 1.35 x liver SUV + 2 x standard deviation liver SUV ) Performance status ( ECOG ) 0 1 Age : ≥ 18 creatinine clearance &gt; 60ml/min measure 24 h urine calculate Cockgroft Gault formula bilirubin ≤ 1.5 time upper limit normal , serum transaminase ( GOT / GPT ) ≤ 3 time ULN leukocytes ≥ 3.5 g / l , platelet ≥ 100 g / l Negative pregnancy test ( determination beta HCG urine serum ) woman childbearing potential A sign consent form implementation medical education Existing distant metastasis ( M1b ) Tumor infiltration tracheobronchial system Previous radiotherapy target thorax Lack ability patient adhere protocol rule Manifest heart failure despite optimal medication &gt; NYHA I exist angina pectoris rest undergo stress without clarification via interventional cardiology / myocardial infarction within last 6 month Existing pregnancy lactation childbearing fertility without use recognize safe method contraception Coexisting malignant diseases exception nonmelanomatuous , localized skin tumor carcinoma situ cervix absence sign consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Potentially R0 - resectable AEG primary tumor category</keyword>
	<keyword>Histologically confirm AEG I-III</keyword>
	<keyword>Functional operability</keyword>
	<keyword>Intense FDG tracer uptake tumor</keyword>
</DOC>